Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats

被引:106
作者
Merodio, M
Irache, JM
Valamanesh, F
Mirshahi, M
机构
[1] Univ Navarra, Ctr Galen, E-31080 Pamplona, Spain
[2] Univ Paris 06, INSERM, E9912, F-75006 Paris, France
关键词
albumin; autoimmune antigens; ganciclovir; intravitreal; nanoparticles; photoreceptors;
D O I
10.1016/S0142-9612(01)00284-8
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Cytomegalovirus (CMV) infection mainly affects endothelial cells of ocular vessels, optic nerve and the retina, resulting in direct or autoimmune damages, uveoretinitis and disturbed vision. The use of colloidal carriers for the intravitreal delivery of ganciclovir may prolong its residence in the eye, minimizing the opacification observed for macroscopic implants. The aim of this work was to evaluate the ocular toxicity induced by the prolonged presence of ganciclovir-loaded bovine serum albumin nanoparticles after their intravitreal injection, The intraocular disposition of these carriers was also studied by immunochemistry. Two weeks post-injection, a significant amount of nanoparticles remained in the vitreous cavity, mainly in a thin layer overlying the retina and in the area close to the blood-aqueous barrier. Their prolonged residence in the eye seemed to be well tolerated and the histological evaluation of the retina, mainly the photoreceptor layer, and adjacent tissues revealed the absence of inflammatory reactions or alterations in the tissue architecture (i.e. cellular infiltrations or vascular inflammation). In addition, nanoparticles neither alter the expression and distribution of arrestin and rhodopsin autoantigens nor the mineralocorticoid receptor. In summary, the vision was not affected by autoimmune phenomena or alterations in the behavior of ophthalmic cells due to the intravitreal injection of these nanoparticles. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1587 / 1594
页数:8
相关论文
共 31 条
[1]   Cytomegalovirus retinitis in patients with AIDS in Europe [J].
Burke, M ;
Yust, I ;
Katlama, C ;
Vardinon, N ;
Clumeck, N ;
Pinching, AJ ;
Ledergerber, B ;
Gatell, JM ;
Chiesi, A ;
Barton, SE ;
Lundgren, JD ;
Pedersen, C .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1997, 16 (12) :876-882
[2]   EXPERIMENTAL AUTOIMMUNE UVEORETINITIS IN MICE - INDUCTION BY A SINGLE ELICITING EVENT AND DEPENDENCE ON QUANTITATIVE PARAMETERS OF IMMUNIZATION [J].
CASPI, RR ;
CHAN, CC ;
LEAKE, WC ;
HIGUCHI, M ;
WIGGERT, B ;
CHADER, GJ .
JOURNAL OF AUTOIMMUNITY, 1990, 3 (03) :237-246
[3]  
CHADER GJ, 1989, INVEST OPHTH VIS SCI, V30, P7
[4]   PATHOLOGY OF EXPERIMENTAL AUTOIMMUNE UVEORETINITIS IN MICE [J].
CHAN, CC ;
CASPI, RR ;
NI, M ;
LEAKE, WC ;
WIGGERT, B ;
CHADER, GJ ;
NUSSENBLATT, RB .
JOURNAL OF AUTOIMMUNITY, 1990, 3 (03) :247-255
[5]  
COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348
[6]   Biomaterials used in the posterior segment of the eye [J].
Colthurst, MJ ;
Williams, RL ;
Hiscott, PS ;
Grierson, I .
BIOMATERIALS, 2000, 21 (07) :649-665
[7]   The blood-ocular barriers: past, present, and future [J].
Cunha-Vaz, JG .
DOCUMENTA OPHTHALMOLOGICA, 1997, 93 (1-2) :149-157
[8]   PREVENTION OF EXPERIMENTAL AUTOIMMUNE UVEORETINITIS BY ACTIVE IMMUNIZATION WITH AUTOANTIGEN-SPECIFIC MONOCLONAL-ANTIBODIES [J].
DEKOZAK, Y ;
MIRSHAHI, M ;
BOUCHEIX, C ;
FAURE, JP .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (04) :541-547
[9]  
ELSAMALIGY MS, 1997, DRUG DELIV, V3, P93
[10]   GANCICLOVIR - A REVIEW OF ITS ANTIVIRAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN CYTOMEGALOVIRUS INFECTIONS [J].
FAULDS, D ;
HEEL, RC .
DRUGS, 1990, 39 (04) :597-638